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channelopathies  were  known,  but  most 
of these drugs were used empirically and 
were found to act on ion channels after-
ward. Now our knowledge about their role 
in diseases have validated ion channels as 
very promising druggable targets.
What are the difficulties encountered 
in ion channel drug discovery? A major 
problem of ion channel drugs regards the 
side effects. An ion channel type is often 
expressed  in  many  cell  types,  and  it  is 
important to target the ill tissue without 
altering the normal function of the oth-
ers. Let’s take the example of voltage-gated 
sodium channels, which are expressed in 
many excitable tissues including the heart 
and the central nervous system. The use 
of sodium channel blockers to counteract 
hyper-excitability  in  peripheral  tissues, 
such as the skeletal muscle in myotonia 
or the nociceptive neuron in neuropathic 
pain, can be significantly limited by the side 
action on cardiac or CNS sodium channels. 
Thus the International Association for the 
Study of Pain recommends orally available 
sodium channel blockers as third-line treat-
ment in neuropathic pain, mainly because 
of  their  potential  side  effects  (Dworkin 
et  al.,  2007).  Up  to  now,  to  limit  these 
unwanted effects, a peculiarity of sodium 
channel blockers was exploited, that is the 
use-dependence – the higher the frequency 
of action potential firing, the greater is 
the block of sodium channels – allowing 
a rather specific action of drugs in hyper-
excited cells. A more recent successful ther-
apy based on a channel gating-dependent 
mechanism of action is that of ranolazine 
in angina pectoris, which appears to inhibit 
quite  specifically  the  guilty  late  sodium 
current that is increased in the ischemic 
myocyte (Chaitman, 2006). An other man-
ner to limit the side effects is to restrain 
body exposure when it is possible, such as 
with  topical  lidocaine  for  post-herpetic 
pain or intrathecal ziconotide for severe 
chronic pain. On an other hand, the search 
for drugs specific to channel subtypes has 
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In the last decade, only a few new ion channel 
drugs have reached the market according to 
the Food and Drug Administration. These 
include  nateglinide,  a  non-  sulfonylurea 
blocker of KATP channel used in type II 
diabetes;  ziconotide,  a  N-type  calcium 
channel  blocker  against  severe  chronic 
pain; pregabalin, a calcium channel a2δ 
subunit ligand indicated for neuropathic 
pain; ranolazine, a blocker of late sodium 
current for chronic angina pectoris; and 
lubiprostone,  a  ClC-2  chloride  channel 
activator for chronic idiopathic constipa-
tion. In the meantime, the sodium channel 
blocker mexiletine, indicated as a class IIb 
antiarrhythmic drug but used off-label in 
many disorders of membrane excitability, 
was withdrawn from the market except in 
Japan. While a clinical trial was launched 
last  year  to  confirm  the  effectiveness  of 
mexiletine against muscle stiffness in non-
dystrophic myotonia, myotonic patients, 
and their physicians have now to consider 
shifting to other drugs and defining new 
therapy rules.
Nonetheless it is widely acknowledged 
that research activity of the pharmaceutical 
community in ion channel field has been 
tremendously  increasing  in  recent  years 
(Conte Camerino et al., 2007). Such activity 
continues to investigate sectors tradition-
ally covered by ion channel drugs, such as 
cardiovascular diseases, epilepsies, neuro-
pathic pain, and diabetes. For instance, new 
calcium channel blockers, which constitute 
one  of  the  major  classes  of  therapeutic 
agents,  have  been  identified  by  pharma-
cological  and  radiochemical  techniques 
and largely studied by patch-clamp. Thus 
this research field is not abandoned and 
novel compounds are currently considered 
(Godfraind, 2005, 2006). Now it also regards 
new sectors with great potential such as can-
cer,  inflammation,  immunomodulation, 
kidney diseases, and pathogen infection. In 
addition, ion channels are straightforward 
druggable targets for a number of rare dis-
eases, including the ion channelopathies.
Ion  channelopathies  are  monogenic 
hereditary  diseases  due  to  mutations  in 
genes  encoding  ion  channel  subunits 
(Conte Camerino et al., 2008). The term 
was coined about 20 years ago to define 
the skeletal muscle disorders due to muta-
tions  in  sodium,  chloride,  and  calcium 
genes with symptoms ranging from loss of 
excitability to over-excitability. Since then 
many other genetic diseases affecting the 
whole range of tissues have been linked to 
ion channel gene defects. The discovery of 
ion channelopathies may be considered as 
a revolution for the study of ion channels, 
the third one after the pioneering work of 
Nobel prize-winning Hodgkin and Huxley 
in the 1950s, who have defined the basis 
for selective ion currents across the plasma 
membrane, and the invention of the patch-
clamp technique by Neher and Sakmann 
in the 1970s, Nobel prize in 1991, which 
allows to record any kind of ion channel 
activity in almost all cell types (Hodgkin 
and Huxley, 1952; Hamill et al., 1981). An 
other recent outstanding advancement in 
ion channel research was the 3D resolution 
of channel structure by X-ray crystallogra-
phy (MacKinnon, 2004).
The discovery of channelopathies coin-
cides with the combination of electrophysi-
ological and molecular genetic techniques. 
The possibility to study the dysfunction of 
a mutated channel in an heterologous sys-
tem of expression and to correlate it with 
the clinical phenotype have tremendously 
increased our knowledge about the role of 
ion channel in physiology and pathology. 
Importantly the ion channelopathies can 
also serve as paradigms to understand the 
more complex and frequent multifactorial 
diseases. At the same time, the use of knock-
down and knock-out animal experiments 
have also significantly contributed to the 
understanding  of  ion  channel  contribu-
tion to diseases. Altogether these progresses 
have underscored the therapeutic potential 
of ion channel modulators. Drugs acting on 
ion channels were already in use before the Conte Camerino and Desaphy  Ion channel pharmacology and channelopathies
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to improve ion channel surface membrane 
expression, which may be impaired by path-
ogenic mutations (Amaral, 2006).
In  addition  to  pharmacotherapy,  ion 
channels have been often neglected as tar-
gets for toxicants or as undesired targets for 
drugs. Now, preclinical testing is required by 
the FDA and other agencies for registration 
of pharmaceuticals, which consists in assess-
ing the risk potential of the test substance 
to block cardiac hERG potassium channels 
and delay ventricular repolarization. Many 
pharma/biotech(s) also routinely test their 
drug candidates on cardiac hNav1.5 sodium 
channels before to go ahead in development. 
This may allow to discard potential cardio-
toxic compounds early during drug devel-
opment. The progress of high throughput 
systems to investigate ion channel pharma-
cology will certainly allow to increase this 
kind of toxicological assays.
In  conclusion,  the  human  genome 
project has identified more than 400 genes 
encoding ion channel subunits, and many 
have been already shown to play a critical 
role in diseases, either directly or indirectly. 
It is likely that this knowledge will further 
increase by taking advantage of the most 
modern methodologies, such as the omics 
technologies. In the next future, the grand 
challenge of ion channel research will con-
sist in finding more specific drugs able to 
block selectively ion channel subtypes or ion 
channel mutants to allow the development 
of new and safer pharmacotherapy and con-
cretize ion channel   pharmacogenetics from 
the bench side to the clinics.
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proven  challenging.  For  instance,  nine 
genes in the human genome are known 
to encode voltage-gated sodium channel 
subtypes with high sequence homology, 
which are expressed in a tissue-selective 
manner. No specific drug for the skeletal 
muscle hNav1.4 sodium channel is avail-
able yet, and drugs relatively selective for 
hNav1.7  and  hNav1.8  channels,  which 
are mainly expressed in peripheral nocic-
eptive neurons, have been described only 
very recently (Jarvis et al., 2007; Williams 
et al., 2007).
Drug screening on ion channels has been 
a slow process for a long time, due to the lack 
of high throughput techniques. The gold 
standard  for  studying  ion  channel  func-
tion and pharmacology is the patch-clamp 
technique (Hamill et al., 1981). Although 
the amazing signal and time resolutions of 
this technique allow an in-depth descrip-
tion of intimate drug–channel interaction, 
it remains a laborious and time consum-
ing experiment requiring skilled operators, 
which limits its application as a screening 
platform. In the last decade, high through-
put  automated  electrophysiological  plat-
forms  have  been  developed,  which  are 
more suited for large drug screenings such 
as those performed in the modern pharma-
ceutical industry (Castle et al., 2009). This 
is expected to accelerate the individuation 
and lead optimization of drug candidates. 
Nevertheless, because of the complex inter-
action of drugs with channel gating, it is 
likely that the patch-clamp technique will 
remain irreplaceable for many years in many 
circumstances. This later consideration is 
especially true for searching drug candidates 
in ion channelopathies, because the muta-
tions may modify drug–channel interaction 
either directly or secondarily to alteration 
of gating. More drastically,   voltage-sensor 
mutations  of  hNav1.4  sodium  channels 
responsible for periodic paralysis have been 
shown to create a new pathway for cations 
parallel to the sodium ion conducting pore 
of  the  channel,  which  implies  searching 
drugs acting radically differently on mutant 
compared to wild-type channels (Sokolov 
et al., 2010). Moreover, other technologies 
would be also needed to screen ion chan-
nels for   pharmacological chaperones able 